Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 1,173 | 220 | 1,350 | 3,355 | 473 |
| Cost of Goods | 720 | 423 | 908 | 83 | 77 |
| Gross Profit | 453 | -203 | 442 | 3,272 | 396 |
| Operating Expenses | 22,026 | 18,182 | 17,813 | 20,484 | 31,053 |
| Operating Income | -20,853 | -17,962 | -16,463 | -17,129 | -30,580 |
| Interest Expense | 1,169 | 1,167 | 985 | 239 | 0 |
| Other Income | -20 | -17 | -15 | -5 | 17 |
| Pre-tax Income | -22,042 | -19,146 | -17,463 | -17,373 | -30,563 |
| Income Tax | 9 | -16 | 8 | -199 | 11 |
| Net Income Continuous | -22,051 | -19,130 | -17,471 | -17,174 | -30,574 |
| Net Income Discontinuous | N/A | -66 | 76 | 69 | -106 |
| Net Income | $-22,051 | $-19,196 | $-17,395 | $-17,105 | $-30,680 |
| EPS Basic Total Ops | -559.52 | -456.78 | -495.24 | -502.38 | -914.65 |
| EPS Basic Continuous Ops | -558.54 | -452.02 | -497.62 | -504.76 | -914.65 |
| EPS Basic Discontinuous Ops | N/A | -5.53 | 2.38 | 2.38 | 0.00 |
| EPS Diluted Total Ops | -559.52 | -456.78 | -495.24 | -502.38 | -914.65 |
| EPS Diluted Continuous Ops | -558.54 | -452.02 | -497.62 | -504.76 | -914.65 |
| EPS Diluted Discontinuous Ops | N/A | -5.53 | 2.38 | 2.38 | 0.00 |
| EBITDA(a) | $-20,436 | $-17,318 | $-15,667 | $-16,569 | $-30,129 |